The FDA is setting up a task force to advise the agency on products derived from nanotechnology. The members of the task force will recommend ways to fill any policy or knowledge gaps in the field, with a particular focus on any health threats that could be posed by the science of the very small. A host of biotech companies have been using nanotechnology to develop or reformulate new therapies. Oftentimes by changing a drug's dose to microscopic-sized particles researchers can change the way a therapy works. That creates new opportunities, as well as possible new pitfalls.
- here's the UPI report on the FDA